The present invention describes novel nitrosated and / or nitrosylated
cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and / or nitrosylated
cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases
nitric oxide, stimulates endogenous synthesis of
nitric oxide, elevates endogenous levels of
endothelium-derived relaxing factor or is a substrate for
nitric oxide synthase, and / or optionally, at least one therapeutic agent, such as, steroids,
nonsteroidal antiinflammatory compounds (NSAID), 5-
lipoxygenase (5-LO) inhibitors,
leukotriene B4 (LTB4)
receptor antagonists,
leukotriene A4 (LTA4)
hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) inhibitors, H2antagonists, antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible
nitric oxide synthase inhibitors, opioids, analgesics,
Helicobacter pylori inhibitors,
proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. The present invention also provides novel compositions comprising at least one parent COX-2 inhibitor and at least one nitric
oxide donor, and, optionally, at least one therapeutic agent. The present invention also provides kits and methods for treating
inflammation, pain and fever; for treating and / or improving the gastrointestinal properties of COX-2 inhibitors; for facilitating
wound healing; for treating and / or preventing renal
toxicity; and for treating and / or preventing other disorders resulting from elevated levels of
cyclooxygenase-2.